13F Holdings
中文EN

ONCY ONCOLYTICS BIOTECH INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 1129928 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-639.3%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets228.7%
Debt / equity—
Current ratio0.89x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.77x
Accruals ratio-145.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31 · USDFY20242024-12-31 · USDFY2023*2023-12-31 · CADFY2022*2022-12-31 · CADFY2021*2021-12-31 · CAD
Income statement
Revenue————0
R&D expense$13.31M$15.44M17.71M15.43M12.92M
SG&A expense$15.41M$10.10M16.08M11.49M13.31M
Operating income-$28.73M-$25.54M-33.79M-26.92M-26.23M
Pretax income-$28.68M-$22.70M-27.66M-24.75M-26.25M
Income tax$79,000$95,00097,00084,00049,000
Net income-$28.76M-$22.79M-27.75M-24.84M-26.30M
EBITDA-$28.66M-$25.45M-33.71M-26.83M-26.11M
EPS (basic)-0.30-0.30-0.41-0.43-0.49
EPS (diluted)-0.30-0.30-0.41-0.43-0.49
Weighted avg. shares (diluted)95.86M76.48M67.62M58.03M53.51M
Banking
Net interest income—-139,000CAD-71,00076,000-92,000
Balance sheet
Cash & equivalents$5.20M$11.08M34.91M11.67M41.26M
Current assets$6.84M$12.44M38.17M35.68M44.90M
PP&E, net$228,000$286,000282,000356,000392,000
Total assets$7.58M$13.42M38.82M37.33M45.88M
Current liabilities$6.10M$4.88M4.24M3.94M2.69M
Total liabilities$11.38M$10.12M11.26M10.83M9.78M
Shareholders' equity-$3.80M$3.30M$19.60MUSD26.50M36.10M
Shares outstanding108.02M80.02M———
Cash flow statement
Operating cash flow-$20.11M-$19.88M———
Capital expenditure$6,000$174,0008,00055,000286,000
Free cash flow-$20.12M-$20.06M———
Investing cash flow-$6,000-$174,00020.22M-20.40M-286,000
Financing cash flow$14.12M$5.03M31.99M12.21M33.02M
Depreciation & amortization$70,000$87,00081,00093,000130,000
Stock-based compensation$3.10M$1.98M1.92M2.38M3.83M

Free plan shows the latest 5 periods; Pro shows all 11 🔒

· This company uses different currencies across periods or line items (e.g. USD convenience translations in annual reports). Each column header shows its currency and cells in a different currency are marked; do not compare figures across currencies. Charts use only periods in the latest period's currency.

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.